X
CPRX

Xponance’s Catalyst Pharmaceutical CPRX Stock Holding History

Xponance’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$380K Buy
15,363
+1,804
+13% +$43K ﹤0.01% 1148
2025
Q4 		$316K Sell
13,559
-565
-4% -$12.6K ﹤0.01% 1150
2025
Q3 		$278K Sell
14,124
-3,694
-21% -$76K ﹤0.01% 1205
2025
Q2 		$387K Sell
17,818
-870
-5% -$20.5K ﹤0.01% 1046
2025
Q1 		$453K Sell
18,688
-75
-0.4% -$1.69K ﹤0.01% 968
2024
Q4 		$392K Buy
18,763
+1,189
+7% +$25.5K ﹤0.01% 1031
2024
Q3 		$349K Buy
+17,574
New +$326K ﹤0.01% 1043

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Xponance's CPRX Position: Q1 2026 in Review

Xponance increased its Catalyst Pharmaceutical (CPRX) stake by 13% in Q1 2026, buying an estimated $43K and bringing the position to 15,363 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

Xponance first reported a position in CPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $453K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Xponance held 15,363 shares of Catalyst Pharmaceutical worth $380K as of Q1 2026.
  • Xponance bought 1,804 Catalyst Pharmaceutical shares in Q1 2026, an estimated $43K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1148 holding.
  • Xponance first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 7 quarters since.
  • Xponance's Catalyst Pharmaceutical position peaked at $453K in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.